苯磺酸左旋氨氯地平片治疗中老年患者轻中度原发性高血压的疗效观察(1)
摘 要：目的 探討苯磺酸左旋氨氯地平片治疗中老年患者轻中度原发性高血压的临床效果及其安全性。方法 选取我院2017年4月～2018年4月收治的126例患轻中度原发性高血压的中老年患者，随机分为对照组和观察组，每组63例。对照组选用硝苯地平缓释片治疗，观察组采取苯磺酸左旋氨氯地平片治疗，12周后，比较两组患者治疗前后血压的变化、治疗总有效率和不良反应发生率。结果 观察组治疗12周的血压为(130.89±7.00)/(80.89±6.37)mmHg，血压控制情况优于对照组的(150.52±3.20)/(90.44±4.67)mmHg，差异具有统计学意义(P<0.05)。观察组治疗总有效率为92.06%，高于对照组的74.60%，差异具有统计学意义(P<0.05)。观察组不良反应发生率为1.59%，低于对照组的6.35%，差异具有统计学意义(P<0.05)。结论 苯磺酸左旋氨氯地平片治疗高血压的效果优于硝苯地平缓释片，控制患者血压，且不良反应少，安全性高。
关键词：苯磺酸左旋氨氯地平片;硝苯地平缓释片;高血压
, http://www.100md.com
中图分类号：R544.1 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.16.037
文章编号：1006-1959(2018)16-0120-03
Efficacy of Levamlodipine Besylate Tablets in Treatment of Mild to Moderate Essential Hypertension in Middle-aged and Elderly Patients
ZUO Hong-liang
(Department of Pharmacy，Shanggao County People's Hospital，Shanggao 336400，Jiangxi，China)
, 百拇医药
Abstract：Objective To investigate the clinical efficacy and safety of levamlodipine besylate tablets in the treatment of mild to moderate essential hypertension in middle-aged and elderly patients.Methods From April 2017 to April 2018，126 middle-aged and elderly patients with mild to moderate essential hypertension were randomly divided into control group and observation group with 63 cases in each group.The control group was treated with nifedipine sustained-release tablets，while the observation group was treated with levamlodipine besylate tablets.After 12 weeks，the changes of blood pressure，total effective rate and incidence of adverse reactions were compared between the two groups before and after treatment.Results The blood pressure of the observation group was(130.89±7.00)/(80.89±6.37)mmHg after 12 weeks of treatment.The blood pressure control of the observation group was better than that of the control group(150.52±3.20)/(90.44±4.67)mmHg，the difference was statistically significant(P<0.05).The total effective rate of the observation group was 92.06%，which was higher than that of the control group 74.60%，the difference was statistically significant(P< 0.05).The incidence of adverse reactions in the observation group was 1.59%，which was lower than that in the control group 6.35%，the difference was statistically significant(P<0.05).Conclusion Levamlodipine besylate tablet is superior to nifedipine sustained-release tablet in the treatment of hypertension with less adverse reactions and high safety., 百拇医药(左洪亮)
关键词：苯磺酸左旋氨氯地平片;硝苯地平缓释片;高血压
, http://www.100md.com
中图分类号：R544.1 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.16.037
文章编号：1006-1959(2018)16-0120-03
Efficacy of Levamlodipine Besylate Tablets in Treatment of Mild to Moderate Essential Hypertension in Middle-aged and Elderly Patients
ZUO Hong-liang
(Department of Pharmacy，Shanggao County People's Hospital，Shanggao 336400，Jiangxi，China)
, 百拇医药
Abstract：Objective To investigate the clinical efficacy and safety of levamlodipine besylate tablets in the treatment of mild to moderate essential hypertension in middle-aged and elderly patients.Methods From April 2017 to April 2018，126 middle-aged and elderly patients with mild to moderate essential hypertension were randomly divided into control group and observation group with 63 cases in each group.The control group was treated with nifedipine sustained-release tablets，while the observation group was treated with levamlodipine besylate tablets.After 12 weeks，the changes of blood pressure，total effective rate and incidence of adverse reactions were compared between the two groups before and after treatment.Results The blood pressure of the observation group was(130.89±7.00)/(80.89±6.37)mmHg after 12 weeks of treatment.The blood pressure control of the observation group was better than that of the control group(150.52±3.20)/(90.44±4.67)mmHg，the difference was statistically significant(P<0.05).The total effective rate of the observation group was 92.06%，which was higher than that of the control group 74.60%，the difference was statistically significant(P< 0.05).The incidence of adverse reactions in the observation group was 1.59%，which was lower than that in the control group 6.35%，the difference was statistically significant(P<0.05).Conclusion Levamlodipine besylate tablet is superior to nifedipine sustained-release tablet in the treatment of hypertension with less adverse reactions and high safety., 百拇医药(左洪亮)